Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.

Prostate-specific membrane antigen (PSMA) is a well-characterized target that is overexpressed selectively on prostate cancer cells. PSMA antibody-drug conjugate (ADC) is a fully human IgG1 monoclonal antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE), which is designed to specifically bind PSMA-positive cells, internalize, and then release its cytotoxic payload into the cells. PSMA ADC has demonstrated potent and selective antitumor activity in preclinical models of advanced prostate cancer. A Phase 1 study was conducted to assess the safety, pharmacokinetics, and preliminary antitumor effects of PSMA ADC in subjects with treatment-refractory prostate cancer.

In this first-in-man dose-escalation study, PSMA ADC was administered by intravenous infusion every three weeks to subjects with progressive metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel chemotherapy. The primary endpoint was to establish a maximum tolerated dose (MTD). The study also examined the pharmacokinetics of the study drug, total antibody, and free MMAE. Antitumor effects were assessed by measuring changes in serum prostate-specific antigen (PSA), circulating tumor cells (CTCs), and radiologic imaging.

Fifty-two subjects were administered doses ranging from 0.4 to 2.8 mg/kg. Subjects had a median of two prior chemotherapy regimens and prior treatment with abiraterone and/or enzalutamide. Neutropenia and peripheral neuropathy were identified as important first-cycle and late dose-limiting toxicities, respectively. The dose of 2.5 mg/kg was determined to be the MTD. Pharmacokinetics were approximately dose-proportional with minimal drug accumulation. Reductions in PSA and CTCs in subjects treated with doses of ≥1.8 mg/kg were durable and often concurrent.

In an extensively pretreated mCRPC population, PSMA ADC demonstrated acceptable toxicity. Antitumor activity was observed over dose ranges up to and including 2.5 mg/kg. The observed anti-tumor activity supported further evaluation of this novel agent for the treatment of advanced metastatic prostate cancer.

The Prostate. 2019 Jan 20 [Epub ahead of print]

Daniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, Anthony Mega, Mark T Fleming, Joe J Stephenson, Richard Frank, Neal D Shore, Robert Dreicer, Edward F McClay, William R Berry, Manish Agarwal, Vincent A DiPippo, Yakov Rotshteyn, Nancy Stambler, William C Olson, Stephen A Morris, Robert J Israel

Department of Urology, Yale University, New Haven, Connecticut., Dana-Farber Cancer Institute, Boston, Massachusetts., Comprehensive Cancer Center of Nevada, Las Vegas, Nevada., Miriam Hospital, Providence, Rhode Island., Virginia Oncology Associates, Hampton, Virginia., Cancer Centers of the Carolinas, Greenville, South Carolina., Western CT Health Network, Norwalk, Connecticut., Carolina Urologic Research Center, Myrtle Beach, South Carolina., University of Virginia Cancer Center, Charlottesville, Virginia., California Cancer Associates for Research & Excellence, Encinitas, California., Cancer Centers of North Carolina, Raleigh, North Carolina., Associates in Oncology and Hematology, Rockville, Maryland., Progenics Pharmaceuticals, Inc., New York, New York.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe